KR100444369B1 - The memory increasing novel compound ginseno-jk from ginseng hairy roots and the manufacturing method of the ginseno-jk - Google Patents
The memory increasing novel compound ginseno-jk from ginseng hairy roots and the manufacturing method of the ginseno-jk Download PDFInfo
- Publication number
- KR100444369B1 KR100444369B1 KR10-2001-0026805A KR20010026805A KR100444369B1 KR 100444369 B1 KR100444369 B1 KR 100444369B1 KR 20010026805 A KR20010026805 A KR 20010026805A KR 100444369 B1 KR100444369 B1 KR 100444369B1
- Authority
- KR
- South Korea
- Prior art keywords
- ginseno
- ginsenoside
- composition
- memory
- ginseng
- Prior art date
Links
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 26
- 241000208340 Araliaceae Species 0.000 title claims abstract description 25
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 25
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 25
- 230000015654 memory Effects 0.000 title abstract description 18
- 238000004519 manufacturing process Methods 0.000 title description 7
- 230000001965 increasing effect Effects 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 40
- 229930182494 ginsenoside Natural products 0.000 claims abstract description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000000284 extract Substances 0.000 claims abstract description 12
- 229920005989 resin Polymers 0.000 claims abstract description 12
- 239000011347 resin Substances 0.000 claims abstract description 12
- 229930182490 saponin Natural products 0.000 claims abstract description 11
- 150000007949 saponins Chemical class 0.000 claims abstract description 11
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims abstract description 9
- 230000006883 memory enhancing effect Effects 0.000 claims description 9
- SYWDWCWQXBUCOP-UHFFFAOYSA-N benzene;ethene Chemical group C=C.C1=CC=CC=C1 SYWDWCWQXBUCOP-UHFFFAOYSA-N 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims description 2
- MHSBXIYDCOYMJB-UHFFFAOYSA-N ethene;ethylbenzene Chemical group C=C.CCC1=CC=CC=C1 MHSBXIYDCOYMJB-UHFFFAOYSA-N 0.000 claims description 2
- XSQNOFMFKVYSNL-UHFFFAOYSA-N ethene;toluene Chemical group C=C.CC1=CC=CC=C1 XSQNOFMFKVYSNL-UHFFFAOYSA-N 0.000 claims description 2
- 238000001179 sorption measurement Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 12
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 abstract description 8
- 238000000034 method Methods 0.000 abstract description 5
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 4
- 206010039966 Senile dementia Diseases 0.000 abstract description 4
- 235000013361 beverage Nutrition 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- 235000013305 food Nutrition 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract description 2
- 238000010828 elution Methods 0.000 abstract 1
- 229940089161 ginsenoside Drugs 0.000 description 26
- 238000012360 testing method Methods 0.000 description 12
- 241000700159 Rattus Species 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 235000017709 saponins Nutrition 0.000 description 9
- 239000002994 raw material Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000001149 cognitive effect Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 229940107131 ginseng root Drugs 0.000 description 4
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000012347 Morris Water Maze Methods 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 3
- 235000020710 ginseng extract Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000003446 memory effect Effects 0.000 description 3
- 230000006993 memory improvement Effects 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000006886 spatial memory Effects 0.000 description 3
- 101800000414 Corticotropin Proteins 0.000 description 2
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 2
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 102000007451 Steroid Receptors Human genes 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 108091008723 corticosteroid receptors Proteins 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 description 1
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000018791 negative regulation of catalytic activity Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000003568 synaptosome Anatomy 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/035—Organic compounds containing oxygen as heteroatom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/30—Other Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Abstract
본 발명은 조직배양한 인삼모상근을 이용하여 기억력을 증강시키는 신규한 조성물 진세노-JK를 제조하는 방법과 제조된 진세노-JK의 용도에 관한 것이다.The present invention relates to a method for preparing a new composition ginseno-JK that enhances memory using ginseng hairy root in tissue culture and the use of the prepared ginseno-JK.
조직배양하여 수득한 인삼 모상근을 70%의 주정 또는 에탄올로 추출한 다음, 이 추출물을 벤젠에틸렌 수지에 흡착시키고, 20% 주정으로 비사포닌 성분을 용출 제거한 후, 60 ~ 80% 주정으로 목적하는 성분을 용출하여 제조된 조성물로서, 구성성분이 진세노사이드 Rb₁, Rb₂, Rc, Rd, Re, Rg₁이고, 진세노사이드 Rb1, Rb2, Rc, Rd 각각의 함량이 Rg₁의 1/2 이하인 신규의 조성물 진세노-JK를 제공한다.Ginseng hairy root obtained by tissue culture was extracted with 70% alcohol or ethanol, and then the extract was adsorbed on benzeneethylene resin, and eluted and removed the non-saponin component with 20% alcohol, and then the desired component was 60-80% alcohol. as the elution to prepare the composition, the components of the binary ginsenosides Rb₁, Rb₂, Rc, Rd, Re, and Rg₁, ginsenoside Rb 1, Rb 2, Rc, Rd are each one-half or less of new content Rg₁ Provides the composition Ginseno-JK.
제조된 진세노-JK는 기억력을 증강시키는 효과가 있으며 노인성 치매증상의 예방 및 개선제, 음료, 식품의 원료 등으로도 활용할 수 있다.The manufactured ginseno-JK has the effect of enhancing memory and can be used as an agent for preventing and improving senile dementia symptoms, beverages, and foods.
Description
본 발명은 조직배양한 인삼 모상근을 이용하여 기억력을 증강시키는 신규한 조성물 진세노-JK를 제조하는 방법과 제조된 진세노-JK의 용도에 관한 것이다.The present invention relates to a method for preparing a novel composition ginseno-JK that enhances memory using ginseng hairy roots cultured and the use of the prepared ginseno-JK.
인삼은 실험동물을 이용한 여러 가지 기억학습 실험모델에서 학습기능의 증진과 기억력을 개선시켜 지적 수행능력을 향상시키는 효능이 있다는 것이 보고되어 왔다.Ginseng has been reported to be effective in improving intellectual performance by improving learning function and memory in various memory learning experimental models using experimental animals.
중추 콜린 신경계는 기억과 학습기증에 매우 중요한 역할을 하며, 노인성 치매증은 콜린성 신경계의 기능저하와 밀접한 관련이 있는 것으로 보고되고 있다[Bartus RT, Dean RL 등, 1982, Science 217, 408-414;ibid,1985, Pharmacol. Biochem. Behav. 23;125-135].The central choline nervous system plays a very important role in memory and learning donation, and senile dementia has been reported to be closely associated with the deterioration of cholinergic nervous system [Bartus RT, Dean RL et al., 1982, Science 217, 408-414; ibid; , 1985, Pharmacol. Biochem. Behav. 23; 125-135.
아세칠콜린 함량분포가 많은 대뇌피질과 뇌 해마(海馬)조직으로부터 분리한 시납토좀(synaptosome)을 이용한 시험관 시험에서 인삼의 대표적인 사포닌인 진세노사이드-Rg₁과 진세노사이드-Rb₁은 아세칠콜린의 합성 전구체인 콜린(choline)의 흡수를 증가시켜 아세칠콜린 방출을 촉진하는 효과를 나타낸다. 진세노사이드-Rb₁을 랫드에 투여 시에도 콜린의 흡수가 증가하여 진세노사이드-Rb₁이 기억학습 개선약물로 분류될 수 있다는 가능성이 제시되었다[Benishin CG, Lee R, Wang LCH and Liu HJ, 1991, Pharmacology 42, 223-229;Benishin CG, 1992, Neurochem INT. 21(1): 1-5].In vitro tests using synaptosomes isolated from cerebral cortex and brain hippocampus with high distribution of acetylcholine content, ginsenoside-Rg₁ and ginsenoside-Rb₁, the representative saponins of ginseng, It has the effect of promoting the release of acylcholine by increasing the absorption of choline, a synthetic precursor. The administration of ginsenoside-Rb₁ to rats increased choline uptake, suggesting that ginsenoside-Rb₁ could be classified as a memory-learning drug [Benishin CG, Lee R, Wang LCH and Liu HJ, 1991 , Pharmacology 42, 223-229; Bennishin CG, 1992, Neurochem INT. 21 (1): 1-5].
한편, 고려인삼의 PT계 사포닌과 진세노사이드-Rg₁은 중추 도파민 신경활성을 증대시키는 뇌기능 개선약물(Cetrophenoxine, N-methyl-D-aspartate)과 유사한 작용을 나타낸다는 보고도 있다(Lee SC. You KH adn Yamamoto R, 1995, Korean J Ginseng Sci.,17(3) 187-195).On the other hand, PT-based saponins and ginsenoside-Rg ₁ of Korean ginseng have been reported to have a similar effect to the brain function improving drug (Cetrophenoxine, N-methyl-D-aspartate) to increase central dopamine neuronal activity (Lee SC. You KH adn Yamamoto R, 1995, Korean J Ginseng Sci., 17 (3) 187-195).
또한 이유기의 마우스에 진세노사이드-Rg₁ 및 진세노사이드-Rb₁을 4주간 연속 투여시 뇌의 발육촉진(뇌 중량, 대뇌피질 두께 등 증가)과 기억학습 행동에유효한 효과가 있음이 관찰 되었다[Zhang JT, Yang Y, and Qu Zw, Jiang XY, Liu M,(1993) Proc. 6th Int'I Ginseng Symp., 69-73].In addition, four consecutive weeks of ginsenoside-RgR and ginsenoside-Rb₁ in weaning mice were found to be effective in promoting brain development (increase brain weight, cortical thickness, etc.) and memory learning behaviors. Zhang JT, Yang Y, and Qu Zw, Jiang XY, Liu M, (1993) Proc. 6th Int'I Ginseng Symp., 69-73].
기억학습 기능의 증강효과와 관련하여 흰쥐(young, and old rats)의 전뇌 피질, 선조체, 해마 등의 여러 뇌조직 부위를 이용한 생체 외 시험에서 진세노사이드-Rg₁은 Cyclic AMP 포스포다이에스테라제(phosphodiesterase)의 효소활성을 현저히 억제함으로써 2차 메신저(second messenger)로서 호르몬과 신경 전달물질의 반응을 매개하는 cyclic AMP의 함량저하를 억제한다는 연구결과가 제시되어 진세노사이드-Rg₁의 중추효과를 뒷받침 해주고 있다(Stancheva SL and Alova L(1993) Gen. Pharmacol. 24(6), 1459-1462).Ginsenoside-Rg® is a Cyclic AMP phosphodiesterase in vitro studies using various brain tissues such as the cerebral cortex, striatum and hippocampus in young, and old rats. Inhibition of enzyme activity of phosphodiesterase significantly inhibits the cyclic AMP content that mediates the reaction between hormones and neurotransmitters as a second messenger, supporting the central effect of ginsenoside-RgR. Stancheva SL and Alova L (1993) Gen. Pharmacol. 24 (6), 1459-1462.
또한, 진세노사이드-Rg₁은 항건망증 효과를 나타내는 신경 펩타이드인 ACTH(adrenocorticotropin)의 혈장 중 함량도 증가시킨다고 보고되었다[Hiai S, Yokoyama Hand Yano S(1979), Endocr. Japon, 26, 661-665]. 진세노사이드-Rg₁은 고령쥐(28개월)의 뇌 해마조직 사이토졸의 저하된 코티코 스테로이드 수용체 결합능력을 젊은 쥐(3개월)의 수준으로 회복시켜주는 효과도 관찰되었다.In addition, ginsenoside-Rg R has been reported to increase the plasma content of ACTH (adrenocorticotropin), a neuropeptide exhibiting anti- forgetful effect [Hiai S, Yokoyama Hand Yano S (1979), Endocr. Japon, 26, 661-665. Ginsenoside-Rg® was also found to restore the decreased corticosteroid receptor binding capacity of cerebral hippocampal cytosol in elderly rats (28 months) to the level of young rats (3 months).
진세노사이드-Re에 관해서도 스코폴라민(scopolamine)에 의해 손상된 기억력을 경감시켜 주는 효과가 관찰되었다[Yoshimasa Y, Masaya H, Hideshi K, Eur. J. Pharmacol. 312(1996) 149-151]. 방향 또는 장소를 찾거나 인식하는 이른바 공간인지 기억능을 평가하는 방사미로(放射迷路)나 모리스 수 미로(Morris water maze) 시험은 콜린 신경계 기능 감퇴와 관련되는 인식기능 결손에 매우 민감한 시험 방법으로 알려지고 있다(Robert K, McNamara and Ronald WS, 1992, Pharmacol.Biochem. Behav. 41, 529-538)As for ginsenoside-Re, an effect of reducing memory impaired by scopolamine was observed [Yoshimasa Y, Masaya H, Hideshi K, Eur. J. Pharmacol. 312 (1996) 149-151. The so-called radiation maze or Morris water maze test, which evaluates so-called spatial cognitive memory to find or recognize directions or places, is a very sensitive test method for cognitive deficits associated with cholinergic nervous system decline. (Robert K, McNamara and Ronald WS, 1992, Pharmacol. Biochem. Behav. 41, 529-538)
한편, 본 발명 출원인의 한국특허출원 1996-020085(인삼 음료 및 그 제조방법)에는, 인삼추출물에 비타민과 기능성 소재, 유화제, 향미 보조제를 첨가하여 만든 기억력을 증진효능을 갖는 인삼음료에 관한 것이 공지되어 있으나, 구성성분이 다양하며, 본 발명과는 기술내용이 다른 것이다.Meanwhile, Korean Patent Application No. 1996-020085 (Ginseng drink and its manufacturing method) of the applicant of the present invention discloses a ginseng beverage having a memory enhancing effect made by adding a vitamin, a functional material, an emulsifier, and a flavor supplement to ginseng extract. However, the components are various, the technical content is different from the present invention.
또한, 본 발명 출원인의 한국특허출원 1998-0016211(사포닌 고함유 인삼추출물 제조방법)에는, 원료삼 사포닌 추출물을 벤젠에칠렌 등의 인공합성수지에 흡착시킨 다음, 묽은 주정으로 비사포닌 성분을 용출 제거시킨 후, 진한 주정으로 사포닌 고함유 추출물을 용출하여 제조하는 방법이 나와 있으나, 원재료가 일반근이며, 추출용매인 주정의 농도도 본 발명보다 높기 때문에, 본발명과는 목적이 다르고 제조된 추출물의 구성 성분도 다르며, 약리 효과에 대해서는 언급이 없다.In addition, Korean Patent Application No. 1998-0016211 (Method of manufacturing saponin-containing ginseng extract) of the present inventors adsorbs the raw ginseng saponin extract to an artificial synthetic resin such as benzene ethylene, and then elutes and removes the non-saponin component with dilute alcohol. In the present invention, a method of eluting saponin high content extract with a dark spirit is shown, but since the raw material is common root, and the concentration of alcohol, which is an extraction solvent, is higher than the present invention, the purpose of the present invention is different from that of the present invention, It is different and there is no mention of pharmacological effects.
또한, 한국특허출원 1994-028987(두뇌활성제 연질 캡슐의 제조방법)에 도코사핵사엔사(DNA)함유 어유에 인삼 엑기스, 대두 레시틴, 토코페롤 등을 첨가하여 두뇌 활성화 및 노인성 치매 예방을 위한 연질 캡슐에 관한 것이 나와 있으나, 본 발명과는 그 기술구성내용이 다른 것이다.In addition, Korean patent application 1994-028987 (Method of manufacturing soft brain capsules) is added to docosa nucleated saensa (DNA) fish oil to add ginseng extract, soybean lecithin, tocopherol, soft capsule for brain activation and prevention of senile dementia. It is related to, but the technical configuration is different from the present invention.
또한, 한국특허출원 1998-0017429(치매병 예방 및 치료증 생약 조성물)에는 인삼, 남성, 천마, 석창포 등을 혼합한 조성물의 열수 또는 알콜 추출물에 관한 것이 있으나, 본 발명과는 기술구성이 다른 것이다.In addition, Korean Patent Application No. 1998-0017429 (a herbal composition for preventing and treating dementia) relates to a hydrothermal or alcohol extract of a composition in which ginseng, male, cheonma, and changchangpo are mixed, but the technical configuration is different from the present invention. .
본 발명은 대량 조직배양한 인삼 모상근을 이용함으로써 원료 수급을 원활히 하고, 인체에 무해한 주정을 추출 용매로 하여 특정 농도와 조건으로 진세노사이드 조성물을 추출하여 제조함으로써 기억력 증강 효과가 뛰어난 진세노사이드 조성물을 제공하는데 있다.The present invention facilitates the supply of raw materials by using ginseng hairy roots cultured in large tissues, and extracts ginsenoside compositions at specific concentrations and conditions by using alcohol as an extraction solvent, which is harmless to the human body, thereby having an excellent memory enhancing effect. To provide.
도1은 본 발명의 진세노-JK를 제조하는 방법1 is a method for producing ginseno-JK of the present invention
도2는 정상 랫드의 기억력 개선 테스트 결과2 is a memory test results of normal rats
도3은 단기적 공간인지 기억능력 테스트 결과Figure 3 is a short-term spatial cognitive memory test results
도4는 단기적 공간 기억력 개선에 미치는 진세노-JK의 투여 용량별 1일차 효과Fig. 4 shows the daily effect of ginseno-JK by doses on short-term spatial memory improvement.
도5는 단기적 공간 기억력 개선에 미치는 진세노-JK의 투여 용량별 2일차 효과Figure 5 Effect of Day 2 by Ginseno-JK Dose on Short-term Spatial Memory Improvement
본 발명은 조직배양한 인삼 모상근으로부터 기억력 증강 효과가 뛰어난 진세노사이드 조성물을 제공한다.The present invention provides a ginsenoside composition excellent in memory enhancing effect from tissue cultured ginseng hairy root.
본 발명의 진세노사이드 조성물은, 조직배양하여 수득한 인삼 모상근을 70%의 주정 또는 에탄올로 추출한 다음, 이 추출물을 벤젠에틸렌 수지에 흡착시키고, 20% 주정으로 비사포닌 성분을 용출 제거한 후, 60 ∼ 80% 주정으로 목적하는 성분을 용출하여 제조된 조성물로서, 구성 성분은 진세노사이드 Rb₁, Rb₂, Rc, Rd, Re, Rg₁이고, 진세노사이드 Rb₁, Rb₂, Rc, Rd 각각의 함량이 Rg₁의 1/2 이하인 신규의 조성물로서, 본 발명자들이 이것을 진세노-JK로 명명하였다.In the ginsenoside composition of the present invention, the ginseng hairy root obtained by tissue culture was extracted with 70% alcohol or ethanol, and then the extract was adsorbed onto benzeneethylene resin, and the non-saponin component was eluted and removed. A composition prepared by eluting a desired component with -80% alcohol, wherein the constituents are ginsenosides Rb ', Rb2, Rc, Rd, Re, and Rg', and the content of each ginsenoside Rb ', Rb2, Rc, and Rd is Rg'. As a novel composition of less than 1/2, we named it Ginseno-JK.
일반 인삼근A를 원료로 하여, 진세노사이드-JK 제조와 동일한 방법으로 하여 제조된 진세노사이드 조성물을 진세노사이드-JA 라 명명하고, 이의 성분함량을 분석하고, 기억력 증강효과 비교 실험을 하였다.The ginsenoside composition prepared by the same method as the ginsenoside-JK preparation using ginseng root A as a raw material was named ginsenoside-JA, and its component content was analyzed and the memory enhancing effect was compared. .
진세노사이드-JA의 구성 성분은 진세노사이드 Rb₁, Rb₂, Rc, Rd, Re, Rg₁으로서 진세노사이드-JK와 같으나, 진세노사이드 Rb₁의 함량이 Rg₁의 1.45 배 이상이었다.The components of ginsenoside-JA are ginsenosides Rb ', Rb2, Rc, Rd, Re and Rg', which are the same as ginsenoside-JK, but the content of ginsenoside Rb 'is 1.45 times higher than that of Rg'.
일반 인삼근B를 원료로 하여, 진세노사이드-JK 제조시와 동일한 방법으로 하여 제조된 진세노사이드 조성물을 진세노사이드-JB 라 명명하고, 이의 성분함량을 분석하고, 기억력 증강효과 비교 실험을 하였다.The ginsenoside composition prepared by the same method as in the preparation of ginsenoside-JK, using ginseng root B as a raw material, was named ginsenoside-JB, and its component content was analyzed and a comparison experiment of memory enhancement effect was performed. It was.
진세노사이드-JB의 구성 성분은 진세노사이드 Rb₁, Rb₂, Rc, Rd, Re, Rg₁으로서 진세노사이드-JK와 같으나, 진세노사이드 Rb₁의 함량이 Rg₁의 3.61 배 이상이었다.The components of ginsenoside-JB were ginsenosides Rb ', Rb2, Rc, Rd, Re, and Rg', which were the same as ginsenoside-JK, but the content of ginsenoside Rb 'was 3.61 times higher than that of Rg'.
제조된 진세노-JA와 진세노-JB 및 진세노-JK의 기억력 증강 효과를 비교 확인하기 위해 동물실험을 실시하였다.Animal experiments were conducted to compare and confirm the memory enhancing effects of the prepared ginseno-JA and ginseno-JB and ginseno-JK.
랫드를 사용하여 모리스 수미로(Morris water mage) 실험으로 단기적 공간인지 기억력 개선 테스트 결과, 진세노-JK 투여군이, 진세노-JA 투여군 또는 진세노-JB 투여군보다 기억증강 효과가 훨씬 높았다.In the Morris water mage experiment using rats, the short-term spatial cognitive memory improvement test showed that the ginseno-JK group had a much higher memory effect than the ginseno-JA group or the ginseno-JB group.
랫드를 이용한 진세노-JK의 투여용량별 기억력 개선 효과는 4∼10mg/kg에서 효과가 높았다.The memory-improving effect of ginseno-JK in the rats was high at 4-10 mg / kg.
한편, 본 발명의 진세노사이드 조성물 진세노-JK 는 일반 인삼근으로부터 진세노사이드 성분을 추출하여 적절히 조합하여 만들 수도 있다.In addition, the ginsenoside composition ginseno-JK of this invention can also be made by extracting ginsenoside component from general ginseng root and combining them suitably.
또한, 추출시 사용하는 흡착수지로는 에칠 벤젠에칠렌, 2-메틸 벤젠에칠렌, 2-메칠 프로필레닉산 에스테르 수지도 사용이 가능하다.In addition, as the adsorptive resin used for extraction, ethyl benzene ethylene, 2-methyl benzene ethylene, 2-methyl propylenic acid ester resin can also be used.
이하 본 발명을 실시예와 비교예 및 동물실험 결과를 들어 자세히 설명하지만, 이들에 의해 본 발명이 제한되는 것은 아니다.Hereinafter, the present invention will be described in detail with reference to Examples, Comparative Examples, and animal experiments, but the present invention is not limited thereto.
< 실시예1 > 인삼 모상근으로부터 진세노사이드 조성물의 제조Example 1 Preparation of Ginsenoside Composition from Ginseng Hairy Roots
조직배양한 인삼 모상근을 수득하여 100g을 원료로 사용했다.Tissue cultured ginseng hairy root was obtained and 100 g was used as a raw material.
인삼 모상근에 70%의 주정을 시료 무게의 7 배량 가하고 80℃에서 4시간씩 3회 반복하여 추출한 후 여과하였다.70% alcohol was added to the ginseng hairy root 7 times the weight of the sample, and the resultant was repeatedly extracted three times at 80 ° C. for 4 hours and filtered.
주정 추출물을 감압 농축하여 알콜을 제거한 다음 물로 희석하여 벤젠에칠렌 수지에 서서히 통과시켜 사포닌을 흡착시켰다.The alcohol extract was concentrated under reduced pressure to remove alcohol, diluted with water, and slowly passed through benzeneethylene resin to adsorb saponin.
수지무게의 10 배량의 물로 세척한 다음, 수지무게 5배량의 20% 주정으로 각각 용출시켜 비사포닌 성분을 제거하였다.After washing with 10 times the weight of the resin, and then eluted with 20% alcohol of 5 times the weight of the resin to remove the non-saponin components.
수지무게의 10 배 량의 60% 주정으로 용출시켜 진세노사이드 조성물을 수득하였다.Ginsenoside composition was obtained by eluting with 10% of 60 times the alcohol content of the resin weight.
수득된 진세노사이드 조성물을 TLC 정성분석 하였다.The ginsenoside composition obtained was subjected to TLC qualitative analysis.
수득된 진세노사이드 조성물의 성분별 함량을 HPLC 로 분석하였다.The content of each component of the obtained ginsenoside composition was analyzed by HPLC.
분석결과 진세노사이드 조성물의 성분과 조성비는 표1과 같다.As a result of analysis, the components and composition ratios of the ginsenoside composition are shown in Table 1.
진세노사이드 Rb1:Rg1= 1 : 3.12 였다.Ginsenoside Rb 1 : Rg 1 = 1: 3.12.
표1. 진세노사이드 조성물의 성분별 조성함량Table 1. Composition content of each ginsenoside composition
[단위:dry extract(%)][Unit: dry extract (%)]
<실시예2> 인삼 모상근으로부터 진세노사이드 조성물의 제조Example 2 Preparation of Ginsenoside Composition from Ginseng Hairy Roots
조직배양한 인삼모상근을 수득하여 100g을 원료로 사용했다.Tissue cultured ginseng hairy root was obtained and 100 g was used as a raw material.
이하 실시예1과 같은 방법으로 수행하되, 추출 주정농도를 80 % 로 하여 진세노사이드 조성물을 얻고 TLC 및 HPLC 분석을 실시하였다.It was carried out in the same manner as in Example 1 below, to obtain a ginsenoside composition with an extraction alcohol concentration of 80% to perform a TLC and HPLC analysis.
그 결과는 표2와 같으며, 진세노사이드 Rb1:Rg1= 1 : 2.34 였다.The results are shown in Table 2, and ginsenosides Rb 1 : Rg 1 = 1: 2.34.
표2. 진세노사이드 조성물의 성분별 조성함량Table 2. Composition content of each ginsenoside composition
[단위:dry extract(%)][Unit: dry extract (%)]
실시예 1, 2 이외에 여러 차례의 제조실험 및 동물실험을 반복하여, 실시예 1, 2와 같은 방법으로 제조된 진세노사이드 조성물로서, 성분은 진세노사이드 Rb₁, Rb₂, Rc, Rd, Re, Rg₁이고, 진세노사이드 Rb₁, Rb₂, Rc, Rd 각각의 함량이 Rg₁의 1/2 이하인 신규의 본 발명 조성물을 , 본 발명자들이 진세노-JK라 명명하였다.A ginsenoside composition prepared in the same manner as in Examples 1 and 2 by repeating several manufacturing experiments and animal experiments in addition to Examples 1 and 2, and the components are ginsenosides Rb ', Rb2, Rc, Rd, Re, The inventors named the present invention a new invention composition wherein Rg 'is a content of ginsenosides Rb', Rb2, Rc, and Rd equal to or less than 1/2 of Rg '.
< 비교예1 > 일반근 A로 부터의 진세노사이드 조성물 진세노-JA의 제조Comparative Example 1 Preparation of Ginsenoside Composition Ginseno-JA from General Root A
시중에서 판매되고 있는 6 년근 인삼을 구입하여, 100g을 원료로 사용하였다.A 6-year-old ginseng on the market was purchased and 100 g was used as a raw material.
이하 실시예1과 같은 방법으로 진세노사이드 조성물을 얻고 진세노-JA로 명명하고 TLC 및 HPLC 분석을 실시하였다.Hereinafter, a ginsenoside composition was obtained in the same manner as in Example 1, named Ginseno-JA, and TLC and HPLC analysis were performed.
분석결과 진세노-JA의 성분과 조성비는 표3과 같았다.As a result of analysis, the composition and composition ratio of Ginseno-JA were as shown in Table 3.
진세노사이드 Rb1:Rg1= 1.45 : 1 이었다.Ginsenoside Rb 1 : Rg 1 = 1.45: 1.
표3. 진세노-JA의 진세노사이드 함량Table 3. Ginsenoside Content of Ginseno-JA
[단위:dry extract(%)][Unit: dry extract (%)]
< 비교예2 > 일반근 B로부터 진세노사이드 조성물 진세노-JB의 제조<Comparative Example 2> Preparation of ginsenoside composition ginseno-JB from common muscle B
시중에서 판매되고 있는 6 년근 인삼을 구입하여, 인삼근 동체를 제거하고 잔뿌리를 채취하여 100g을 원료로 사용했다.A 6-year-old ginseng on the market was purchased, and the ginseng root body was removed, and a small root was collected and 100 g was used as a raw material.
이하 실시예1과 같은 방법으로 진세노사이드 조성물을 제조하고, 진세노-JB로 명명하고 TLC 및 HPLC 분석을 실시하였다.Hereinafter, a ginsenoside composition was prepared in the same manner as in Example 1, named Ginseno-JB, and TLC and HPLC analysis were performed.
진세노-JB의 성분과 조성비는 표4와 같다.The components and composition ratios of ginseno-JB are shown in Table 4.
진세노사이드 Rb1:Rg1= 3.61 : 1 이었다.Ginsenoside Rb 1 : Rg 1 = 3.61: 1.
표4. 진세노-JB의 진세노사이드 함량Table 4. Ginsenoside content of ginseno-JB
[단위:dry extract(%)][Unit: dry extract (%)]
[실험예]Experimental Example
상기 실시예에서 제조한 본 발명의 조성물 진세노-JK와 비교예에서 제조한 진세노-JA 및 진세노-JB의 기억력 증강 효과를 비교 확인하기 위하여 동물실험을 실시하였다.Animal experiments were performed to compare and confirm the memory enhancing effects of the composition ginseno-JK of the present invention prepared in the above example and the ginseno-JA and ginseno-JB prepared in the comparative example.
1. 실험재료 및 실험동물1. Experimental Materials and Animals
가. 실험재료end. Experimental material
상술한 실시예1, 비교예1, 비교예2에서 제조한 조성물 진세노-JK, 진세노-JA, 진세노-JB와 대조군으로서 생리식염수를 사용하였다.Physiological saline was used as the control ginseno-JK, ginseno-JA, ginseno-JB and the control prepared in Example 1, Comparative Example 1, Comparative Example 2 described above.
나. 실험동물I. Laboratory animals
랫드(Sparague Dawley rat) 수놈 (180 ∼ 200g)을 한 조에 10∼15마리씩 배정하여 각 실험을 실시하였다.Sparague Dawley rat males (180-200 g) were assigned to each group of 10-15 animals and each experiment was performed.
다. 실험장치All. Experiment apparatus
1) 모리스 수미로(Morris water maze) 장치를 사용하였다.1) Morris water maze apparatus was used.
2. 실험 및 효과 비교2. Experiment and Effect Comparison
(1) 랫드의 학습 후 기억력 생성 테스트(1) the test of memory generation after learning of rats
각 시료를 복강 투여 후 30분 후 실험을 실시하였다.Each sample was tested 30 minutes after intraperitoneal administration.
모리스 수 미로(Morris water maze)에서 8세션(session)에 걸친 학습 훈련 후 푸르브 테스트(Probe test)를 실시하였다.The Probe test was conducted after eight sessions of training in the Morris water maze.
플랫드 폼을 제거하고 스위밍 테스트(Swimming test)를 실시하여 플랫드 폼이 있던 4/1분면 내에 랫드가 머무르는 시간(retention time)을 측정하여 D영역에 대한 기억능력이 생성되었는 지를 확인하였다.By removing the flat foam and performing a swimming test, the retention time of the rat in the 4/1 quadrant of the flat foam was measured to determine whether the memory for the D region was generated.
그 결과는 도2와 같으며 대조군 (생리식염수), 진세노-JK(10mg/kg), 진세노-JA(10mg/kg), 진세노-JB(10mg/kg)에서 모두 정상적인 기억 생성력을 나타냈다.The results are shown in FIG. 2 and showed normal memory production in the control group (physiological saline), ginseno-JK (10 mg / kg), ginseno-JA (10 mg / kg), and ginseno-JB (10 mg / kg). .
(2) 단기적 공간인지 기억능력 테스트(2) Short-term spatial cognitive memory test
기억 학습 훈련이 완료된 랫드들에 대하여 본래 위치(D)의 플랫드 폼을 다른 위치(B)로 옮겨, 그 새로운 목표물을 찾아가는데 걸린 수영시간을 테스트 하였다.Rats who had completed memory learning training were transferred to their original position (D) and moved to another position (B) to test their swimming time to find their new target.
테스트 결과는 도3과 같이 진세노-JK를 투여한 군에서만 기억능력의 향상이 유의적이었다.As a result of the test, the improvement of memory was significant only in the group administered with ginseno-JK as shown in FIG. 3.
(3) 진세노-JK의 투여 용량별 단기적 공간기억력 개선효과 테스트(3) Short-term spatial memory improvement effect test by Ginseno-JK dose
진세노-JK의 투여용량을 달리하여 기억능력 개선효과를 검정하였다.Different doses of ginseno-JK were tested to improve memory capacity.
제1일차 결과는 도4에, 제2일차 결과는 도5에 나타냈다.The first day results are shown in FIG. 4, and the second day results are shown in FIG. 5.
진세노-JK의 용량별 기억개선 효과는 4mg/kg부터 유의적으로 나타났으며 진세노-JK의 기억력개선의 유효농도는 4∼10mg/kg에서 효과가 높았다.Ginseno-JK dose-dependently improved memory effect from 4mg / kg, and the effective concentration of ginseno-JK memory effect was high at 4 ~ 10mg / kg.
조직배양하여 수득한 인삼 모상근으로부터 기억력 증강 효과가 뛰어난 조성물 진세노-JK를 대량 제공한다.The ginseng hairy root obtained by tissue culture provides a large amount of the composition ginseno-JK with an excellent memory enhancing effect.
제조된 진세노-JK 는 기억력을 증강시키는 효과가 뛰어나며, 노인성 치매 증상의 예방 및 개선제, 음료, 식품의 원료 등으로 사용할 수 있다.The prepared ginseno-JK has an excellent effect of enhancing memory and can be used as an agent for preventing and improving senile dementia symptoms, beverages, and foods.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2001-0026805A KR100444369B1 (en) | 2001-05-16 | 2001-05-16 | The memory increasing novel compound ginseno-jk from ginseng hairy roots and the manufacturing method of the ginseno-jk |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2001-0026805A KR100444369B1 (en) | 2001-05-16 | 2001-05-16 | The memory increasing novel compound ginseno-jk from ginseng hairy roots and the manufacturing method of the ginseno-jk |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020030078250A Division KR20030088417A (en) | 2003-11-06 | 2003-11-06 | The memory increasing novel compound ginseno-jk from ginseng hairy roots and the manufacturing method of the ginseno-jk |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20020087787A KR20020087787A (en) | 2002-11-23 |
KR100444369B1 true KR100444369B1 (en) | 2004-08-16 |
Family
ID=27705162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2001-0026805A KR100444369B1 (en) | 2001-05-16 | 2001-05-16 | The memory increasing novel compound ginseno-jk from ginseng hairy roots and the manufacturing method of the ginseno-jk |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100444369B1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100452555B1 (en) * | 2004-07-15 | 2004-10-13 | 박용진 | A composition comprising purified extract of wild ginseng having neuronal cell-protecting activity |
KR100802149B1 (en) * | 2005-09-16 | 2008-02-11 | 주식회사 진생사이언스 | Composition for preventing and treating the disease caused by vascular damage |
KR100840764B1 (en) * | 2007-10-01 | 2008-06-23 | 주식회사 진생사이언스 | Health care food for preventing and improving the disease caused by vascular damage |
US20110052730A1 (en) * | 2008-02-19 | 2011-03-03 | Unigen, Inc. | Leaves Extract of Panax sp., a Process of Making the Same and Uses Thereof |
KR101052574B1 (en) * | 2008-11-04 | 2011-07-29 | 씨제이제일제당 (주) | Method for preparing an extract fraction with enhanced ginsenosides Rg1 or Rb1 from ginseng |
WO2013109051A1 (en) * | 2012-01-20 | 2013-07-25 | 씨제이제일제당(주) | Composition for improving memory or concentration containing extract fraction with increased content of ginseng-derived ginsenoside rg3 as active ingredient |
KR101307202B1 (en) * | 2012-09-13 | 2013-09-11 | 한방바이오 주식회사 | Cultured root of mountain ginseng crmg 5 with improved content of ppt type saponin and method of producing the same |
KR20220041656A (en) | 2020-09-25 | 2022-04-01 | 경희대학교 산학협력단 | A method and composition for improving cognition or memory abilities comprising genseong fine root nano powder |
KR20220041655A (en) | 2020-09-25 | 2022-04-01 | 경희대학교 산학협력단 | Composition for improving cognition or memory abilities comprising genseong fine root concentrated extracts and the process for the preparation therof |
-
2001
- 2001-05-16 KR KR10-2001-0026805A patent/KR100444369B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR20020087787A (en) | 2002-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bao et al. | Memory enhancing and neuroprotective effects of selected ginsenosides | |
CA2991773C (en) | Compositions, methods, and medical compositions for treatment of and maintaining the health of the liver | |
US10758585B2 (en) | Beautyberry total glycosides extract and preparation method and use thereof | |
JP5893135B2 (en) | Combinations of active substances that induce the synergistic effect of multiple targeting and their uses | |
KR102478533B1 (en) | Compositions and methods for managing weight | |
CN100500687C (en) | Process for preparing notoginseng triol saponin and use thereof | |
KR100444369B1 (en) | The memory increasing novel compound ginseno-jk from ginseng hairy roots and the manufacturing method of the ginseno-jk | |
CN107522680A (en) | South America amphibious crab chrysanthemum antineoplastic extract and its production and use | |
Wang et al. | The traditional uses, secondary metabolites, and pharmacology of Lycopodium species | |
CN112076126A (en) | Separation method of whitening functional components in hibiscus mutabilis and application of whitening functional components in cosmetics | |
Adaramoye et al. | Endothelium-independent vasodilation induced by kolaviron, a biflavonoid complex from Garcinia kola seeds, in rat superior mesenteric arteries | |
Moreira et al. | The neuroprotective effect of traditional Chinese medicinal plants—A critical review | |
KR101052574B1 (en) | Method for preparing an extract fraction with enhanced ginsenosides Rg1 or Rb1 from ginseng | |
Kim et al. | Anti-inflammatory and anti-oxidant effects of oxypaeoniflorin, paeoniflorin and Paeonia lactiflora cv.‘Red Charm’flower petal extracts in macrophage cells | |
Pereira et al. | Plant alkaloids: production, extraction, and potential therapeutic properties | |
KR20030088417A (en) | The memory increasing novel compound ginseno-jk from ginseng hairy roots and the manufacturing method of the ginseno-jk | |
Wu et al. | Efficient extraction of caffeic acid derivatives from adventitious roots of Echinacea purpurea | |
KR100570803B1 (en) | A process of extracting glabridine from licorice root | |
Chaichana et al. | Response of Stemona alkaloid production in Stemona sp. to chitosan and yeast extract elicitors | |
CN1843418B (en) | Traditional Chinese medicine extract for treating gastroenteritis, its preparation method and traditional Chinese medicine composition containing same | |
Lovkova et al. | Medicinal plants: concentrators and superconcentrators of copper and its role in metabolism of these species | |
KR101319829B1 (en) | A Composition for Preventing or Treating Dementia Comprising an Extracts and Fraction of Row Codonopsis lanceolat and Steamed Codonopsis lanceolata | |
KR20200004574A (en) | Anti-encephalitis composition comprising Liriope platphylla extracts as an effective component | |
Bae et al. | Neuroprotective effects of Eriobotrya japonica and Salvia miltiorrhiza Bunge in in vitro and in vivo models | |
CN115414421B (en) | Extraction method and application of active ingredients of cortex dictamni |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
N231 | Notification of change of applicant | ||
E902 | Notification of reason for refusal | ||
A107 | Divisional application of patent | ||
N231 | Notification of change of applicant | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20091103 Year of fee payment: 6 |
|
LAPS | Lapse due to unpaid annual fee |